Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 14 de 14
Filter
Add more filters










Publication year range
1.
Neurotox Res ; 39(6): 1880-1891, 2021 Dec.
Article in English | MEDLINE | ID: mdl-34487326

ABSTRACT

Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous system presented by autoimmune manifestations. This study aimed at investigating the effects of apamin administration on the activated T cell population in an experimental autoimmune encephalomyelitis (EAE) MS model. Thirty mice underwent EAE induction and were then randomly divided into 5 groups. Three groups received 10, 50, and 100 µg/kg apamin; the fourth group received 1 mg/kg dexamethasone; and the fifth group received the equivalent amount of PBS (phosphate-buffered saline) intraperitoneally. Peripheral CD4 + cell and memory T cell distribution was measured with a flow cytometer every week. Also, CD4 + and CD8 + cell infiltration to the brain was assessed with immunohistochemistry. It was observed that the group receiving 50 µg/kg apamin had a lower EAE score in comparison with the groups receiving 100 µg/kg apamin (p 0.014). Also, peripheral blood memory cells with CD44 + , CD62L - , and CD4 + markers were decreased in apamin-administered groups. Regarding the infiltrated CD8 + cells, a significant decrease (p 0.002) was observed in the group receiving 50 µg/kg apamin compared with the control group. These results indicate that 50-µg/kg doses of apamin had an effective treatment over 14 days; it reduced both the severity of symptoms and the infiltration of CD8 + cells into the CNS. Moreover, it increased myelin density and decreased the circulation of CD62L - , CD44L - , and CD44 + memory T cells. So, it appears that apamin plays a critical role in regulating immunity and reducing the complications of autoimmune MS.


Subject(s)
Apamin/therapeutic use , Blood-Brain Barrier , Multiple Sclerosis/drug therapy , T-Lymphocytes/drug effects , Animals , Apamin/pharmacology , Blood-Brain Barrier/drug effects , Dexamethasone/therapeutic use , Encephalomyelitis, Autoimmune, Experimental/complications , Encephalomyelitis, Autoimmune, Experimental/immunology , Female , Flow Cytometry , Mice , Mice, Inbred C57BL , Multiple Sclerosis/etiology , Multiple Sclerosis/immunology , Multiple Sclerosis/pathology , Myelin Sheath/pathology
3.
Toxins (Basel) ; 12(3)2020 03 19.
Article in English | MEDLINE | ID: mdl-32204567

ABSTRACT

Bee venom is a natural toxin produced by honeybees and plays an important role in defending bee colonies. Bee venom has several kinds of peptides, including melittin, apamin, adolapamine, and mast cell degranulation peptides. Apamin accounts for about 2%-3% dry weight of bee venom and is a peptide neurotoxin that contains 18 amino acid residues that are tightly crosslinked by two disulfide bonds. It is well known for its pharmacological functions, which irreversibly block Ca2+-activated K+ (SK) channels. Apamin regulates gene expression in various signal transduction pathways involved in cell development. The aim of this study was to review the current understanding of apamin in the treatment of apoptosis, fibrosis, and central nervous system diseases, which are the pathological processes of various diseases. Apamin's potential therapeutic and pharmacological applications are also discussed.


Subject(s)
Apamin/therapeutic use , Atherosclerosis/drug therapy , Bee Venoms/chemistry , Central Nervous System/drug effects , Liver Cirrhosis/drug therapy , Potassium Channels, Calcium-Activated/antagonists & inhibitors , Apamin/isolation & purification , Apoptosis/drug effects , Atherosclerosis/metabolism , Central Nervous System/pathology , Cytokines/antagonists & inhibitors , Fibrosis , Humans , Liver Cirrhosis/pathology
4.
Toxins (Basel) ; 7(4): 1126-50, 2015 Apr 01.
Article in English | MEDLINE | ID: mdl-25835385

ABSTRACT

While knowledge of the composition and mode of action of bee and wasp venoms dates back 50 years, the therapeutic value of these toxins remains relatively unexploded. The properties of these venoms are now being studied with the aim to design and develop new therapeutic drugs. Far from evaluating the extensive number of monographs, journals and books related to bee and wasp venoms and the therapeutic effect of these toxins in numerous diseases, the following review focuses on the three most characterized peptides, namely melittin, apamin, and mastoparan. Here, we update information related to these compounds from the perspective of applied science and discuss their potential therapeutic and biotechnological applications in biomedicine.


Subject(s)
Apamin , Melitten , Peptides , Wasp Venoms , Animals , Apamin/pharmacology , Apamin/therapeutic use , Humans , Intercellular Signaling Peptides and Proteins , Melitten/pharmacology , Melitten/therapeutic use , Peptides/pharmacology , Peptides/therapeutic use , Wasp Venoms/pharmacology , Wasp Venoms/therapeutic use
5.
Int J Neuropsychopharmacol ; 17(8): 1295-306, 2014 Aug.
Article in English | MEDLINE | ID: mdl-24661728

ABSTRACT

Parkinson's disease has traditionally been viewed as a motor disorder caused by the loss of dopamine (DA) neurons. However, emotional and cognitive syndromes can precede the onset of the motor deficits and provide an opportunity for therapeutic intervention. Potassium channels have recently emerged as potential new targets in the treatment of Parkinson's disease. The selective blockade of small conductance calcium-activated K+ channels (SK channels) by apamin is known to increase burst firing in midbrain DA neurons and therefore DA release. We thus investigated the effects of systemic administration of apamin on the motor, cognitive deficits and anxiety present after bilateral nigrostriatal 6-hydroxydopamine (6-OHDA) lesions in rats. Apamin administration (0.1 or 0.3 mg/kg i.p.) counteracted the depression, anxiety-like behaviors evaluated on sucrose consumption and in the elevated plus maze, social recognition and spatial memory deficits produced by partial 6-OHDA lesions. Apamin also reduced asymmetric motor deficits on circling behavior and postural adjustments in the unilateral extensive 6-OHDA model. The partial 6-OHDA lesions (56% striatal DA depletion) produced 20% decrease of iodinated apamin binding sites in the substantia nigra pars compacta in correlation with the loss of tyrosine hydroxylase positive cells, without modifying apamin binding in brain regions receiving DAergic innervation. Striatal extracellular levels of DA, not detectable after 6-OHDA lesions, were enhanced by apamin treatment as measured by in vivo microdialysis. These results indicate that blocking SK channels may reinstate minimal DA activity in the striatum to alleviate the non-motor symptoms induced by partial striatal DA lesions.


Subject(s)
Apamin/pharmacology , Behavior, Animal/drug effects , Cognition/drug effects , Dopamine/metabolism , Motor Activity/drug effects , Parkinson Disease, Secondary/psychology , Potassium Channel Blockers/pharmacology , Small-Conductance Calcium-Activated Potassium Channels/antagonists & inhibitors , Animals , Apamin/therapeutic use , Corpus Striatum/drug effects , Corpus Striatum/metabolism , Dose-Response Relationship, Drug , Male , Oxidopamine/toxicity , Parkinson Disease, Secondary/chemically induced , Parkinson Disease, Secondary/complications , Parkinson Disease, Secondary/drug therapy , Potassium Channel Blockers/therapeutic use , Rats , Small-Conductance Calcium-Activated Potassium Channels/metabolism , Substantia Nigra/drug effects , Substantia Nigra/metabolism , Tyrosine 3-Monooxygenase/metabolism
6.
Arch Pharm Res ; 37(8): 1016-31, 2014 Aug.
Article in English | MEDLINE | ID: mdl-24293065

ABSTRACT

Diabetes is one of the leading causes of impaired wound healing. The objective of this study was to develop a bee venom-loaded wound dressing with an enhanced healing and anti-inflammatory effects to be examined in diabetic rats. Different preparations of polyvinyl alcohol (PVA), chitosan (Chit) hydrogel matrix-based wound dressing containing bee venom (BV) were developed using freeze-thawing method. The mechanical properties such as gel fraction, swelling ratio, tensile strength, percentage of elongation and surface pH were determined. The pharmacological activities including wound healing and anti-inflammatory effects in addition to primary skin irritation and microbial penetration tests were evaluated. Moreover, hydroxyproline, glutathione and IL-6 levels were measured in the wound tissues of diabetic rats. The bee venom-loaded wound dressing composed of 10 % PVA, 0.6 % Chit and 4 % BV was more swellable, flexible and elastic than other formulations. Pharmacologically, the bee venom-loaded wound dressing that has the same previous composition showed accelerated healing of wounds made in diabetic rats compared to the control. Moreover, this bee venom-loaded wound dressing exhibited anti-inflammatory effect that is comparable to that of diclofenac gel, the standard anti-inflammatory drug. Simultaneously, wound tissues covered with this preparation displayed higher hydroxyproline and glutathione levels and lower IL-6 levels compared to control. Thus, the bee venom-loaded hydrogel composed of 10 % PVA, 0.6 % Chit and 4 % BV is a promising wound dressing with excellent forming and enhanced wound healing as well as anti-inflammatory activities.


Subject(s)
Anti-Inflammatory Agents/therapeutic use , Apamin/therapeutic use , Chitosan/chemistry , Cross-Linking Reagents/chemistry , Diabetes Mellitus, Experimental/complications , Drug Carriers/chemistry , Polyvinyl Alcohol/chemistry , Wound Healing/drug effects , Alloxan/pharmacology , Animals , Anti-Inflammatory Agents/administration & dosage , Anti-Inflammatory Agents/adverse effects , Anti-Inflammatory Agents/pharmacology , Apamin/administration & dosage , Apamin/adverse effects , Apamin/pharmacology , Bacterial Infections/microbiology , Bacterial Infections/prevention & control , Chemical Phenomena , Chemistry, Pharmaceutical , Drug Compounding , Hydrogels , Male , Rats, Wistar , Skin/drug effects , Skin/injuries , Skin/microbiology , Wound Healing/immunology , Wounds, Penetrating/complications , Wounds, Penetrating/drug therapy , Wounds, Penetrating/immunology , Wounds, Penetrating/microbiology
7.
Dig Dis Sci ; 58(10): 2908-17, 2013 Oct.
Article in English | MEDLINE | ID: mdl-23918150

ABSTRACT

BACKGROUND/AIM: We have previously reported that bee venom (BV) has a protective role against acute pancreatitis (AP). However, the effects of apamin, the major compound of BV, on AP have not been determined. The aim of this study was to evaluate the effects of apamin on cerulein-induced AP. METHODS: AP was induced via intraperitoneal injection of supramaximal concentrations of the stable cholecystokinin analogue cerulein (50 µg/kg) every hour for 6 times. In the apamin treatment group, apamin was administered subcutaneously (10, 50, or 100 µg/kg) at both 18 and 1 h before the first cerulein injection. The mice were sacrificed at 6 h after the final cerulein injection. Blood samples were obtained to determine serum amylase and lipase levels, as well as cytokine production. The pancreas and lung were rapidly removed for morphologic and histological examination, myeloperoxidase (MPO) assay, and real-time reverse transcription-polymerase chain reaction. Furthermore, we isolated the pancreatic acinar cells to specify the role of apamin in AP. RESULTS: Pre-treatment with apamin inhibited histological damage, pancreatic weight/body weight ratio, serum level of amylase and lipase, MPO activity, and cytokine production. In addition, apamin treatment significantly inhibited cerulein-induced pancreatic acinar cell death. Furthermore, apamin treatment inhibited the cerulein-induced activation of c-Jun NH2-terminal kinases (JNK). CONCLUSIONS: These results could suggest that apamin could protect against AP by inhibition of JNK activation.


Subject(s)
Apamin/pharmacology , Apamin/therapeutic use , Ceruletide/adverse effects , MAP Kinase Signaling System/drug effects , Pancreatitis/chemically induced , Pancreatitis/prevention & control , Acute Disease , Animals , Apamin/administration & dosage , Ceruletide/administration & dosage , Cholecystokinin/analogs & derivatives , Cytokines/metabolism , Disease Models, Animal , Injections, Intraperitoneal , Injections, Subcutaneous , MAP Kinase Signaling System/physiology , Mice , Mice, Inbred C57BL , Mitogen-Activated Protein Kinase Kinases/metabolism , NF-kappa B/metabolism , Pancreas/drug effects , Pancreas/metabolism , Pancreas/pathology
8.
Behav Brain Res ; 237: 71-5, 2013 Jan 15.
Article in English | MEDLINE | ID: mdl-22983217

ABSTRACT

Neurofibromatosis 1 (NF1) is a common genetic disorder known to cause a variety of physiological symptoms such as the formation of both benign and malignant tumors, and is also known to cause visuospatial learning deficits. Mouse models of NF1 show increased GTP activation of ras which may alter K+ channels. One candidate K+ channel that may contribute to deficits in NF1 is the SK (small conductance calcium-activated potassium) channel due to its role in regulation of long term potentiation (LTP), a mechanism of learning which has been shown to be impaired in Nf1(+/-) mice. We found that administration of apamin (SK antagonist) either through i.p. injection or micro-osmotic pump to Nf1(+/-) mice significantly improved performance on the water maze task in comparison to saline treated Nf1(+/-) mice on the third day of training and on the corresponding probe test. In this study we demonstrate a possible mechanism for the learning deficits seen in Nf1(+/-) mice and a possible drug therapy for rescuing these deficits.


Subject(s)
Apamin/therapeutic use , Neurofibromatosis 1/drug therapy , Potassium Channel Blockers/therapeutic use , Animals , Disease Models, Animal , Dose-Response Relationship, Drug , Exploratory Behavior/drug effects , Locomotion/drug effects , Locomotion/genetics , Male , Mice , Mice, Transgenic , Neurofibromatosis 1/genetics , Time Factors
9.
J Cardiovasc Pharmacol ; 57(6): 672-81, 2011 Jun.
Article in English | MEDLINE | ID: mdl-21394037

ABSTRACT

Atrial fibrillation (AF) is associated with increased morbidity and is in addition the most prevalent cardiac arrhythmia. Compounds used in pharmacological treatment has traditionally been divided into Na(+) channel inhibitors, ß-blockers, K(+) channel inhibitors, and Ca(2+) channel inhibitors, whereas newer multichannel blockers such as amiodarone and ranolazine have been introduced later. This study was devoted to the evaluation of an acute pacing-induced in vivo model of AF in rats. Antiarrhythmic effects of well-known compounds such as lidocaine, dofetilide, and ranolazine were confirmed in this model. In addition, antiarrhythmic effects of different inhibitors of Ca(2+)-activated small conductance K(+) (SK) channels were demonstrated. Intravenous application of 5 mg/kg of the negative SK channel modulator NS8593 reduced AF duration by 64.5%, and the lowest significantly effective dose was 1.5 mg/kg. A dose-effect relationship was established based on 6 different dose groups. Furthermore, it was demonstrated that the antiarrhythmic effect of NS8593 and other tested drugs was associated with an increase in atrial effective refractory period. The functional role of SK channels was confirmed by 2 other SK channel inhibitors, UCL1684 and apamin, thereby confirming the hypothesis that these channels might constitute a new promising target for antiarrhythmic treatment.


Subject(s)
Anti-Arrhythmia Agents/therapeutic use , Atrial Fibrillation/prevention & control , Cardiac Pacing, Artificial/adverse effects , Potassium Channel Blockers/therapeutic use , Small-Conductance Calcium-Activated Potassium Channels/antagonists & inhibitors , 1-Naphthylamine/administration & dosage , 1-Naphthylamine/analogs & derivatives , 1-Naphthylamine/therapeutic use , Alkanes/therapeutic use , Anesthesia , Animals , Anti-Arrhythmia Agents/administration & dosage , Apamin/therapeutic use , Atrial Fibrillation/drug therapy , Atrial Fibrillation/etiology , Disease Models, Animal , Dose-Response Relationship, Drug , Insect Proteins/therapeutic use , Male , Molecular Targeted Therapy , Potassium Channel Blockers/administration & dosage , Quinolinium Compounds/therapeutic use , Random Allocation , Rats , Rats, Sprague-Dawley , Reaction Time/drug effects , Time Factors
10.
Circ Res ; 108(8): 971-9, 2011 Apr 15.
Article in English | MEDLINE | ID: mdl-21350217

ABSTRACT

RATIONALE: Fibrillation/defibrillation episodes in failing ventricles may be followed by action potential duration (APD) shortening and recurrent spontaneous ventricular fibrillation (SVF). OBJECTIVE: We hypothesized that activation of apamin-sensitive small-conductance Ca(2+)-activated K(+) (SK) channels is responsible for the postshock APD shortening in failing ventricles. METHODS AND RESULTS: A rabbit model of tachycardia-induced heart failure was used. Simultaneous optical mapping of intracellular Ca(2+) and membrane potential (V(m)) was performed in failing and nonfailing ventricles. Three failing ventricles developed SVF (SVF group); 9 did not (no-SVF group). None of the 10 nonfailing ventricles developed SVF. Increased pacing rate and duration augmented the magnitude of APD shortening. Apamin (1 µmol/L) eliminated recurrent SVF and increased postshock APD(80) in the SVF group from 126±5 to 153±4 ms (P<0.05) and from 147±2 to 162±3 ms (P<0.05) in the no-SVF group but did not change APD(80) in nonfailing group. Whole cell patch-clamp studies at 36°C showed that the apamin-sensitive K(+) current (I(KAS)) density was significantly larger in the failing than in the normal ventricular epicardial myocytes, and epicardial I(KAS) density was significantly higher than midmyocardial and endocardial myocytes. Steady-state Ca(2+) response of I(KAS) was leftward-shifted in the failing cells compared with the normal control cells, indicating increased Ca(2+) sensitivity of I(KAS) in failing ventricles. The K(d) was 232±5 nmol/L for failing myocytes and 553±78 nmol/L for normal myocytes (P=0.002). CONCLUSIONS: Heart failure heterogeneously increases the sensitivity of I(KAS) to intracellular Ca(2+), leading to upregulation of I(KAS), postshock APD shortening, and recurrent SVF.


Subject(s)
Heart Failure/metabolism , Heart Ventricles/metabolism , Small-Conductance Calcium-Activated Potassium Channels/biosynthesis , Ventricular Fibrillation/metabolism , Animals , Apamin/therapeutic use , Calcium Signaling/physiology , Heart Failure/drug therapy , Heart Failure/prevention & control , Heart Ventricles/pathology , Rabbits , Secondary Prevention , Small-Conductance Calcium-Activated Potassium Channels/physiology , Ventricular Fibrillation/drug therapy , Ventricular Fibrillation/prevention & control
11.
Exp Parasitol ; 120(3): 280-5, 2008 Nov.
Article in English | MEDLINE | ID: mdl-18703053

ABSTRACT

Potassium channels are essential for cell survival and regulate the cell membrane potential and electrochemical gradient. During its lifecycle, Plasmodium falciparum parasites must rapidly adapt to dramatically variant ionic conditions within the mosquito mid-gut, the hepatocyte and red blood cell (RBC) cytosols, and the human circulatory system. To probe the participation of K(+) channels in parasite viability, growth response assays were performed in which asexual stage P. falciparum parasites were cultured in the presence of various Ca(2+)-activated K(+) channel blocking compounds. These data describe the novel anti-malarial effects of bicuculline methiodide and tubocurarine chloride and the novel lack of effect of apamine and verruculogen. Taken together, the data herein imply the presence of K(+) channels, or other parasite-specific targets, in P. falciparum-infected RBCs that are sensitive to blockade with Ca(2+)-activated K(+) channel blocking compounds.


Subject(s)
Antimalarials/pharmacology , Plasmodium falciparum/drug effects , Potassium Channel Blockers/pharmacology , Animals , Antimalarials/therapeutic use , Apamin/pharmacology , Apamin/therapeutic use , Bicuculline/analogs & derivatives , Bicuculline/pharmacology , Bicuculline/therapeutic use , Humans , Hypoxanthine/metabolism , Indoles/pharmacology , Indoles/therapeutic use , Malaria, Falciparum/drug therapy , Malaria, Falciparum/parasitology , Parasitemia/drug therapy , Parasitemia/parasitology , Plasmodium falciparum/growth & development , Potassium Channel Blockers/therapeutic use , Tritium , Tubocurarine/pharmacology , Tubocurarine/therapeutic use
12.
Pharmacol Ther ; 115(2): 246-70, 2007 Aug.
Article in English | MEDLINE | ID: mdl-17555825

ABSTRACT

Bee venom (BV) therapy (BVT), the therapeutic application of BV, has been used in traditional medicine to treat diseases, such as arthritis, rheumatism, pain, cancerous tumors, and skin diseases. BV contains a variety of peptides, including melittin, apamin, adolapin, the mast-cell-degranulating (MCD) peptide, enzymes (i.e., phospholipase [PL] A(2)), biologically active amines (i.e., histamine and epinephrine), and nonpeptide components which have a variety of pharmaceutical properties. BV has been reported to have anti-arthritis effects in several arthritis models. Melittin, a major peptide component of BV, has anti-inflammatory and anti-arthritis properties, and its inhibitory activity on nuclear factor kappaB (NF-kappaB) may be essential for the effects of BV. The anti-nociceptive effects of BV have also been demonstrated in thermal, visceral, and inflammatory pain models. Apcupoint stimulation (apipuncture) therapy into subcutaneous region may be important in the BV-induced anti-nociceptive effects. Multiple mechanisms, such as activation of the central and spinal opiod receptor, and alpha(2)-adrenergic activity, as well as activation of the descending serotonergic pathway have been suggested. The inhibition of c-Fos expression in the spinal cord by BV apipuncture in several nociceptive models is also reported to be a possible mechanism. BV also has anti-cancer activity. The cell cytotoxic effects through the activation of PLA(2) by melittin have been suggested to be the critical mechanism for the anti-cancer activity of BV. The conjugation of cell lytic peptide (melittin) with hormone receptors and gene therapy carrying melittin can be useful as a novel targeted therapy for some types of cancer, such as prostate and breast cancer.


Subject(s)
Analgesics/therapeutic use , Anti-Inflammatory Agents/therapeutic use , Antineoplastic Agents/therapeutic use , Antirheumatic Agents/therapeutic use , Bee Venoms/therapeutic use , Acupuncture Therapy , Analgesics/chemistry , Analgesics/pharmacology , Animals , Anti-Inflammatory Agents/chemistry , Anti-Inflammatory Agents/pharmacology , Antineoplastic Agents/chemistry , Antineoplastic Agents/pharmacology , Antirheumatic Agents/chemistry , Antirheumatic Agents/pharmacology , Apamin/therapeutic use , Arthritis, Rheumatoid/drug therapy , Bee Venoms/chemistry , Bee Venoms/pharmacology , Humans , Hyaluronoglucosaminidase/therapeutic use , Intercellular Signaling Peptides and Proteins , Melitten/therapeutic use , Peptides/therapeutic use , Skin Diseases/drug therapy
13.
Curr Drug Targets CNS Neurol Disord ; 3(3): 161-7, 2004 Jun.
Article in English | MEDLINE | ID: mdl-15180477

ABSTRACT

In most central neurons, small conductance Ca(2+)-activated K(+) channels (SK channels) contribute to afterhyperpolarizations (AHPs), which control neuronal excitability. The medium AHP has pharmacological properties similar to recombinant SK channels, consistent with the hypothesis that SK channels generate this afterhyperpolarization component. It is still unclear how recombinant SK channels are functionally related to the slow AHP component. Cloned SK channels are heteromeric complexes of SK channel subunits and calmodulin. The channels are activated by Ca(2+) binding to calmodulin that induces conformational changes resulting in channel opening. Channel deactivation is the reverse process brought about by dissociation of Ca(2+) from calmodulin. In the mammalian brain, the three SK channel subunits (SK1-3) display partially overlapping distributions. Most of the higher brain regions such as the neocortex and hippocampus show expression of both genes encoding SK1 and SK2 channels, whereas phylogenetically older brain regions such as the thalamus, basal ganglia, cerebellum, and brainstem show high levels of SK3 gene expression. At present, it is still unclear whether native SK channels are generated as heteromeric or homomeric channels. Peptide toxins such as apamin and scyllatoxin, as well as organic compounds such as quaternary salts of bicuculline, dequalinium, UCL 1684 and UCL 1848 serve as non-specific SK channel blockers. The only known exceptions so far are the scorpion toxin tamapin and the peptide inhibitor Lei-Dab(7), which bind preferentially to SK2. Electrophysiological and behavioral studies indicate that blockade of SK channels by apamin increases excitability, lowers the threshold for the induction of synaptic plasticity, and facilitates hippocampus-dependent memory. The potential value of pharmacological SK channel modulation in various pathological states such as increased epileptiform activity, cognitive impairment, pain, mood disorders and schizophrenia will be discussed.


Subject(s)
Brain/drug effects , Drug Design , Membrane Potentials/drug effects , Mental Disorders/drug therapy , Neurons/drug effects , Potassium Channels, Calcium-Activated/drug effects , Animals , Apamin/pharmacology , Apamin/therapeutic use , Brain/cytology , Brain/physiology , Drug Delivery Systems , Epilepsy/drug therapy , Epilepsy/physiopathology , Humans , Learning/physiology , Membrane Potentials/physiology , Mental Disorders/physiopathology , Mood Disorders/drug therapy , Mood Disorders/physiopathology , Neurons/physiology , Pain/drug therapy , Pain/physiopathology , Potassium Channels/drug effects , Potassium Channels/physiology , Potassium Channels, Calcium-Activated/physiology , Rats , Schizophrenia/drug therapy , Schizophrenia/physiopathology , Small-Conductance Calcium-Activated Potassium Channels , Tissue Distribution
14.
Clin Neurophysiol ; 112(2): 294-9, 2001 Feb.
Article in English | MEDLINE | ID: mdl-11165532

ABSTRACT

OBJECTIVES: To describe a case of equine muscular dystrophy with myotonia. METHODS: A 5-year-old horse presented with hypertrophy and delayed relaxation of the muscles of the hindlimbs from age 2 months. Testicular atrophy developed from 2 years of age. Action and percussion myotonia was associated with weakness in these muscles, and EMG showed diffuse myotonic discharges and myopathic features. Biopsy of the gluteal muscle showed adipose and connective tissue infiltration, marked variation in muscle fibre size, and moth-eaten, ring and whorled fibres. RESULTS: Injection of apamin, a peptide blocker of calcium-activated potassium channels, which inhibits myotonia in human myotonic dystrophy, was ineffective in blocking myotonic discharges. Discharges promptly abated with 2% lidocaine injection. CONCLUSIONS: Myotonia in this horse is associated with dystrophic changes similar to human myotonic dystrophy, though there are some pharmacological differences.


Subject(s)
Horse Diseases , Muscular Dystrophy, Animal/complications , Myotonia/veterinary , Anesthetics, Local/therapeutic use , Animals , Apamin/therapeutic use , Atrophy , Electromyography , Hindlimb , Horse Diseases/drug therapy , Horse Diseases/pathology , Horse Diseases/physiopathology , Horses , Hypertrophy , Lidocaine/therapeutic use , Male , Muscle Relaxation , Muscle Weakness/etiology , Muscle, Skeletal/drug effects , Muscle, Skeletal/pathology , Muscle, Skeletal/physiopathology , Muscular Dystrophy, Animal/drug therapy , Muscular Dystrophy, Animal/pathology , Muscular Dystrophy, Animal/physiopathology , Myotonia/complications , Myotonia/drug therapy , Myotonia/physiopathology , Neural Conduction , Testis/pathology , Treatment Failure
SELECTION OF CITATIONS
SEARCH DETAIL
...